Top Markets
#1 Black Phoenix Black Phoenix +736.57%
#2 Islamic Coin Islamic Coin +146.17%
#3 THORChain THORChain +26.71%
#4 MiL.k Alliance MiL.k Alliance +26.65%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.17%
#6 THORChain Yield THORChain Yield +20.24%
#7 Bless Bless +19.93%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +14.36%
#9 TENDIES TENDIES +14.32%
#10 Tutorial Tutorial +12.78%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rank in Stocks #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Share Price
$93.80
Last synced: 2025-04-28
Market Cap
$2.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Aerovate Therapeutics, Inc. (AVTE)

Category

Healthcare
Revenue for Aerovate Therapeutics, Inc. (AVTE)
Revenue in Jun 2026 TTM: 0.00
According to Aerovate Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 equal to the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aerovate Therapeutics, Inc. from 2019 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH